Questcor Expansion Strategy Pays Off For Acthar

Questcor has successfully revived a decades-old product by raising the drug’s price, securing a new approval in a niche orphan indication in infants and making a commercial push in areas like multiple sclerosis and rheumatoid arthritis.

More from Pricing Debate

More from Market Access